. 2016 Apr 16;6:33. doi: 10.1186/s13613-016-0138-4

Table 3.

Primary and secondary outcomes

Variables	Nebulized heparin (N = 139)	Control (N = 147)	Odds ratio^a (95 % CI)	P
Primary outcome
Ventilator-free days at day 28	14.0 (0.0–23.0)	6.0 (0.0–22.0)		0.459
Ventilator-free days at day 28	(N = 139)	(N = 144)
Secondary outcomes
Overall mortality	34/139 (24.5)	35/147 (23.8)	0.65 (0.50–1.56)^b	0.653
Overall mortality	(N = 139)	(N = 147)	0.65 (0.50–1.56)^b	0.653
PaO₂/FiO₂ at day seven (mmHg)	242.5 (206.0–300.0)	220.2 (179.4–297.7)		0.098
PaO₂/FiO₂ at day seven (mmHg)	(N = 61)	(N = 78)		0.098
LIS at day seven	2.0 (1.0–2.5)	2.2 (1.7–3.0)		0.027
LIS at day seven	(N = 40)	(N = 48)
Pneumonia during hospital stay	48/82 (58.5)	48/106 (45.3)	1.49 (0.79–2.80)	0.219
Pneumonia during hospital stay	(N = 82)	(N = 106)	1.49 (0.79–2.80)	0.219
ICU-free days at day 28	2.9 (0.0–19.0)	0.0 (0.0–14.2)		0.035
ICU-free days at day 28	(N = 78)	(N = 62)		0.035
Hospital-free days at day 28	0.0 (0.0–12.0)	0.0 (0.0–14.0)		0.951
Hospital-free days at day 28	(N = 139)	(N = 147)		0.951

Values are median (IQR), and others are no./total no. (%)

Not all requested data were available for each study

LIS lung injury scores, CI confidence interval, N number of patients

^aAdjusted by: age and baseline PaO₂/FiO₂

^bPresented as hazard ratio adjusted by: age, %TBSA, and baseline PaO₂/FiO₂